Loading…

Safety, efficacy, and impact on gut microbial ecology of a Bifidobacterium longum subspecies infantis LMG11588 supplementation in healthy term infants: a randomized, double-blind, controlled trial in the Philippines

subspecies infantis ( ) may play a key role in infant gut development. This trial evaluated safety, tolerability, and efficacy of LMG11588 supplementation. This randomized, placebo-controlled, double-blind study conducted in the Philippines included healthy breastfed and/or formula-fed infants (14-2...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in nutrition (Lausanne) 2023, Vol.10, p.1319873-1319873
Main Authors: Capeding, Maria Rosario Z, Phee, Loudhie Cyd M, Ming, Chang, Noti, Mario, Vidal, Karine, Le Carrou, Gilles, Frézal, A, Moll, Janne Marie, Vogt, Josef Korbinian, Myers, Pernille Neve, Nielsen, Bjørn Henrik, Boulangé, Claire L, Samuel, Tinu Mary, Berger, Bernard, Cercamondi, Colin Ivano
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c362t-789fdb3e7c24dfb3558706327d895d2f56c45028370fff9094c54398668c79933
container_end_page 1319873
container_issue
container_start_page 1319873
container_title Frontiers in nutrition (Lausanne)
container_volume 10
creator Capeding, Maria Rosario Z
Phee, Loudhie Cyd M
Ming, Chang
Noti, Mario
Vidal, Karine
Le Carrou, Gilles
Frézal, A
Moll, Janne Marie
Vogt, Josef Korbinian
Myers, Pernille Neve
Nielsen, Bjørn Henrik
Boulangé, Claire L
Samuel, Tinu Mary
Berger, Bernard
Cercamondi, Colin Ivano
description subspecies infantis ( ) may play a key role in infant gut development. This trial evaluated safety, tolerability, and efficacy of LMG11588 supplementation. This randomized, placebo-controlled, double-blind study conducted in the Philippines included healthy breastfed and/or formula-fed infants (14-21 days old) randomized for 8 weeks to a control group (CG;  = 77), or any of two experimental groups (EGs): low (Lo-EG; 1*10 CFU/day;  = 75) or high dose (Hi-EG; 1.8*10 CFU/day;  = 76). Primary endpoint was weight gain; secondary endpoints included stooling patterns, gastrointestinal symptoms, adverse events, fecal microbiome, biomarkers, pH, and organic acids. Non-inferiority in weight gain was demonstrated for Hi-EG and Lo-EG vs. CG. Overall, probiotic supplementation promoted mushy-soft stools, fewer regurgitation episodes, and increased fecal acetate production, which was more pronounced in the exclusively breastfed infants (EBF) and positively correlated with abundance. In EBF, fecal pro-inflammatory cytokines (IL-1 beta, IL-8) were reduced. Strain-level metagenomic analysis allowed attributing the increased abundance of in EGs versus CG, to LMG11588 probiotic colonization. Colonization by autochthonous strains was similar between groups. LMG11588 supplementation was associated with normal infant growth, was safe and well-tolerated and promoted a -rich microbiota driven by LMG11588 colonization without disturbing the natural dispersal of autochthonous strains. In EBF, supplementation stimulated microbial metabolic activity and beneficially modulated enteric inflammation.
doi_str_mv 10.3389/fnut.2023.1319873
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_1fbdfd23842e4deda7e8aeac7ba20389</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_1fbdfd23842e4deda7e8aeac7ba20389</doaj_id><sourcerecordid>2909087621</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-789fdb3e7c24dfb3558706327d895d2f56c45028370fff9094c54398668c79933</originalsourceid><addsrcrecordid>eNpNkstuFDEQRVsIRKKQD2CDvGSRmfjRDzc7iEKINAgkQGJn-VGeceS2G9u9GH6U38HDTCJWVS7fOlVS3aZ5TfCaMT5e27CUNcWUrQkjIx_Ys-ac0rFf8Z78fP5fftZc5vyAMSaMdi1pXzZnjJOedhSfN3--SQtlf4XAWqelrpkMBrlplrqgGNB2KWhyOkXlpEego4_bPYoWSfTBWWeiqkJIbpmQj2FbQ15UnkE7yMgFK0NxGW0-3xHScV4_59nDBKHI4ireBbQD6ctujyplOnXkdxWf6iJxcr_BXCETF-VhpbwL9aVjKCl6DwaVdFirUsoO0Ned826eXYD8qnlhpc9weYoXzY-Pt99vPq02X-7ub95vVpr1tKwGPlqjGAyatsYq1nV8wD2jg-FjZ6jtet12mHI2YGvtiMdWdy0bed9zPYwjYxfN_ZFronwQc3KTTHsRpRP_CjFthUzFaQ-CWGWsoYy3FFoDRg7AJUg9KElxvWhlvT2y5hR_LZCLmFzW4L0MEJcsaJ2P-dBTUqXkKK2HyTmBfRpNsDjYQxzsIQ72ECd71J43J_yiJjBPHY9mYH8Bhz-6VQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2909087621</pqid></control><display><type>article</type><title>Safety, efficacy, and impact on gut microbial ecology of a Bifidobacterium longum subspecies infantis LMG11588 supplementation in healthy term infants: a randomized, double-blind, controlled trial in the Philippines</title><source>PubMed Central(OpenAccess)</source><creator>Capeding, Maria Rosario Z ; Phee, Loudhie Cyd M ; Ming, Chang ; Noti, Mario ; Vidal, Karine ; Le Carrou, Gilles ; Frézal, A ; Moll, Janne Marie ; Vogt, Josef Korbinian ; Myers, Pernille Neve ; Nielsen, Bjørn Henrik ; Boulangé, Claire L ; Samuel, Tinu Mary ; Berger, Bernard ; Cercamondi, Colin Ivano</creator><creatorcontrib>Capeding, Maria Rosario Z ; Phee, Loudhie Cyd M ; Ming, Chang ; Noti, Mario ; Vidal, Karine ; Le Carrou, Gilles ; Frézal, A ; Moll, Janne Marie ; Vogt, Josef Korbinian ; Myers, Pernille Neve ; Nielsen, Bjørn Henrik ; Boulangé, Claire L ; Samuel, Tinu Mary ; Berger, Bernard ; Cercamondi, Colin Ivano</creatorcontrib><description>subspecies infantis ( ) may play a key role in infant gut development. This trial evaluated safety, tolerability, and efficacy of LMG11588 supplementation. This randomized, placebo-controlled, double-blind study conducted in the Philippines included healthy breastfed and/or formula-fed infants (14-21 days old) randomized for 8 weeks to a control group (CG;  = 77), or any of two experimental groups (EGs): low (Lo-EG; 1*10 CFU/day;  = 75) or high dose (Hi-EG; 1.8*10 CFU/day;  = 76). Primary endpoint was weight gain; secondary endpoints included stooling patterns, gastrointestinal symptoms, adverse events, fecal microbiome, biomarkers, pH, and organic acids. Non-inferiority in weight gain was demonstrated for Hi-EG and Lo-EG vs. CG. Overall, probiotic supplementation promoted mushy-soft stools, fewer regurgitation episodes, and increased fecal acetate production, which was more pronounced in the exclusively breastfed infants (EBF) and positively correlated with abundance. In EBF, fecal pro-inflammatory cytokines (IL-1 beta, IL-8) were reduced. Strain-level metagenomic analysis allowed attributing the increased abundance of in EGs versus CG, to LMG11588 probiotic colonization. Colonization by autochthonous strains was similar between groups. LMG11588 supplementation was associated with normal infant growth, was safe and well-tolerated and promoted a -rich microbiota driven by LMG11588 colonization without disturbing the natural dispersal of autochthonous strains. In EBF, supplementation stimulated microbial metabolic activity and beneficially modulated enteric inflammation.</description><identifier>ISSN: 2296-861X</identifier><identifier>EISSN: 2296-861X</identifier><identifier>DOI: 10.3389/fnut.2023.1319873</identifier><identifier>PMID: 38162520</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>autochthonous strains ; B. infantis LMG11588 ; Bifidobacterium-rich microbiota ; infant growth ; safety</subject><ispartof>Frontiers in nutrition (Lausanne), 2023, Vol.10, p.1319873-1319873</ispartof><rights>Copyright © 2023 Capeding, Phee, Ming, Noti, Vidal, Le Carrou, Frézal, Moll, Vogt, Myers, Nielsen, Boulangé, Samuel, Berger and Cercamondi.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c362t-789fdb3e7c24dfb3558706327d895d2f56c45028370fff9094c54398668c79933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38162520$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Capeding, Maria Rosario Z</creatorcontrib><creatorcontrib>Phee, Loudhie Cyd M</creatorcontrib><creatorcontrib>Ming, Chang</creatorcontrib><creatorcontrib>Noti, Mario</creatorcontrib><creatorcontrib>Vidal, Karine</creatorcontrib><creatorcontrib>Le Carrou, Gilles</creatorcontrib><creatorcontrib>Frézal, A</creatorcontrib><creatorcontrib>Moll, Janne Marie</creatorcontrib><creatorcontrib>Vogt, Josef Korbinian</creatorcontrib><creatorcontrib>Myers, Pernille Neve</creatorcontrib><creatorcontrib>Nielsen, Bjørn Henrik</creatorcontrib><creatorcontrib>Boulangé, Claire L</creatorcontrib><creatorcontrib>Samuel, Tinu Mary</creatorcontrib><creatorcontrib>Berger, Bernard</creatorcontrib><creatorcontrib>Cercamondi, Colin Ivano</creatorcontrib><title>Safety, efficacy, and impact on gut microbial ecology of a Bifidobacterium longum subspecies infantis LMG11588 supplementation in healthy term infants: a randomized, double-blind, controlled trial in the Philippines</title><title>Frontiers in nutrition (Lausanne)</title><addtitle>Front Nutr</addtitle><description>subspecies infantis ( ) may play a key role in infant gut development. This trial evaluated safety, tolerability, and efficacy of LMG11588 supplementation. This randomized, placebo-controlled, double-blind study conducted in the Philippines included healthy breastfed and/or formula-fed infants (14-21 days old) randomized for 8 weeks to a control group (CG;  = 77), or any of two experimental groups (EGs): low (Lo-EG; 1*10 CFU/day;  = 75) or high dose (Hi-EG; 1.8*10 CFU/day;  = 76). Primary endpoint was weight gain; secondary endpoints included stooling patterns, gastrointestinal symptoms, adverse events, fecal microbiome, biomarkers, pH, and organic acids. Non-inferiority in weight gain was demonstrated for Hi-EG and Lo-EG vs. CG. Overall, probiotic supplementation promoted mushy-soft stools, fewer regurgitation episodes, and increased fecal acetate production, which was more pronounced in the exclusively breastfed infants (EBF) and positively correlated with abundance. In EBF, fecal pro-inflammatory cytokines (IL-1 beta, IL-8) were reduced. Strain-level metagenomic analysis allowed attributing the increased abundance of in EGs versus CG, to LMG11588 probiotic colonization. Colonization by autochthonous strains was similar between groups. LMG11588 supplementation was associated with normal infant growth, was safe and well-tolerated and promoted a -rich microbiota driven by LMG11588 colonization without disturbing the natural dispersal of autochthonous strains. In EBF, supplementation stimulated microbial metabolic activity and beneficially modulated enteric inflammation.</description><subject>autochthonous strains</subject><subject>B. infantis LMG11588</subject><subject>Bifidobacterium-rich microbiota</subject><subject>infant growth</subject><subject>safety</subject><issn>2296-861X</issn><issn>2296-861X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpNkstuFDEQRVsIRKKQD2CDvGSRmfjRDzc7iEKINAgkQGJn-VGeceS2G9u9GH6U38HDTCJWVS7fOlVS3aZ5TfCaMT5e27CUNcWUrQkjIx_Ys-ac0rFf8Z78fP5fftZc5vyAMSaMdi1pXzZnjJOedhSfN3--SQtlf4XAWqelrpkMBrlplrqgGNB2KWhyOkXlpEego4_bPYoWSfTBWWeiqkJIbpmQj2FbQ15UnkE7yMgFK0NxGW0-3xHScV4_59nDBKHI4ireBbQD6ctujyplOnXkdxWf6iJxcr_BXCETF-VhpbwL9aVjKCl6DwaVdFirUsoO0Ned826eXYD8qnlhpc9weYoXzY-Pt99vPq02X-7ub95vVpr1tKwGPlqjGAyatsYq1nV8wD2jg-FjZ6jtet12mHI2YGvtiMdWdy0bed9zPYwjYxfN_ZFronwQc3KTTHsRpRP_CjFthUzFaQ-CWGWsoYy3FFoDRg7AJUg9KElxvWhlvT2y5hR_LZCLmFzW4L0MEJcsaJ2P-dBTUqXkKK2HyTmBfRpNsDjYQxzsIQ72ECd71J43J_yiJjBPHY9mYH8Bhz-6VQ</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Capeding, Maria Rosario Z</creator><creator>Phee, Loudhie Cyd M</creator><creator>Ming, Chang</creator><creator>Noti, Mario</creator><creator>Vidal, Karine</creator><creator>Le Carrou, Gilles</creator><creator>Frézal, A</creator><creator>Moll, Janne Marie</creator><creator>Vogt, Josef Korbinian</creator><creator>Myers, Pernille Neve</creator><creator>Nielsen, Bjørn Henrik</creator><creator>Boulangé, Claire L</creator><creator>Samuel, Tinu Mary</creator><creator>Berger, Bernard</creator><creator>Cercamondi, Colin Ivano</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>DOA</scope></search><sort><creationdate>2023</creationdate><title>Safety, efficacy, and impact on gut microbial ecology of a Bifidobacterium longum subspecies infantis LMG11588 supplementation in healthy term infants: a randomized, double-blind, controlled trial in the Philippines</title><author>Capeding, Maria Rosario Z ; Phee, Loudhie Cyd M ; Ming, Chang ; Noti, Mario ; Vidal, Karine ; Le Carrou, Gilles ; Frézal, A ; Moll, Janne Marie ; Vogt, Josef Korbinian ; Myers, Pernille Neve ; Nielsen, Bjørn Henrik ; Boulangé, Claire L ; Samuel, Tinu Mary ; Berger, Bernard ; Cercamondi, Colin Ivano</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-789fdb3e7c24dfb3558706327d895d2f56c45028370fff9094c54398668c79933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>autochthonous strains</topic><topic>B. infantis LMG11588</topic><topic>Bifidobacterium-rich microbiota</topic><topic>infant growth</topic><topic>safety</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Capeding, Maria Rosario Z</creatorcontrib><creatorcontrib>Phee, Loudhie Cyd M</creatorcontrib><creatorcontrib>Ming, Chang</creatorcontrib><creatorcontrib>Noti, Mario</creatorcontrib><creatorcontrib>Vidal, Karine</creatorcontrib><creatorcontrib>Le Carrou, Gilles</creatorcontrib><creatorcontrib>Frézal, A</creatorcontrib><creatorcontrib>Moll, Janne Marie</creatorcontrib><creatorcontrib>Vogt, Josef Korbinian</creatorcontrib><creatorcontrib>Myers, Pernille Neve</creatorcontrib><creatorcontrib>Nielsen, Bjørn Henrik</creatorcontrib><creatorcontrib>Boulangé, Claire L</creatorcontrib><creatorcontrib>Samuel, Tinu Mary</creatorcontrib><creatorcontrib>Berger, Bernard</creatorcontrib><creatorcontrib>Cercamondi, Colin Ivano</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Directory of Open Access Journals</collection><jtitle>Frontiers in nutrition (Lausanne)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Capeding, Maria Rosario Z</au><au>Phee, Loudhie Cyd M</au><au>Ming, Chang</au><au>Noti, Mario</au><au>Vidal, Karine</au><au>Le Carrou, Gilles</au><au>Frézal, A</au><au>Moll, Janne Marie</au><au>Vogt, Josef Korbinian</au><au>Myers, Pernille Neve</au><au>Nielsen, Bjørn Henrik</au><au>Boulangé, Claire L</au><au>Samuel, Tinu Mary</au><au>Berger, Bernard</au><au>Cercamondi, Colin Ivano</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety, efficacy, and impact on gut microbial ecology of a Bifidobacterium longum subspecies infantis LMG11588 supplementation in healthy term infants: a randomized, double-blind, controlled trial in the Philippines</atitle><jtitle>Frontiers in nutrition (Lausanne)</jtitle><addtitle>Front Nutr</addtitle><date>2023</date><risdate>2023</risdate><volume>10</volume><spage>1319873</spage><epage>1319873</epage><pages>1319873-1319873</pages><issn>2296-861X</issn><eissn>2296-861X</eissn><abstract>subspecies infantis ( ) may play a key role in infant gut development. This trial evaluated safety, tolerability, and efficacy of LMG11588 supplementation. This randomized, placebo-controlled, double-blind study conducted in the Philippines included healthy breastfed and/or formula-fed infants (14-21 days old) randomized for 8 weeks to a control group (CG;  = 77), or any of two experimental groups (EGs): low (Lo-EG; 1*10 CFU/day;  = 75) or high dose (Hi-EG; 1.8*10 CFU/day;  = 76). Primary endpoint was weight gain; secondary endpoints included stooling patterns, gastrointestinal symptoms, adverse events, fecal microbiome, biomarkers, pH, and organic acids. Non-inferiority in weight gain was demonstrated for Hi-EG and Lo-EG vs. CG. Overall, probiotic supplementation promoted mushy-soft stools, fewer regurgitation episodes, and increased fecal acetate production, which was more pronounced in the exclusively breastfed infants (EBF) and positively correlated with abundance. In EBF, fecal pro-inflammatory cytokines (IL-1 beta, IL-8) were reduced. Strain-level metagenomic analysis allowed attributing the increased abundance of in EGs versus CG, to LMG11588 probiotic colonization. Colonization by autochthonous strains was similar between groups. LMG11588 supplementation was associated with normal infant growth, was safe and well-tolerated and promoted a -rich microbiota driven by LMG11588 colonization without disturbing the natural dispersal of autochthonous strains. In EBF, supplementation stimulated microbial metabolic activity and beneficially modulated enteric inflammation.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>38162520</pmid><doi>10.3389/fnut.2023.1319873</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2296-861X
ispartof Frontiers in nutrition (Lausanne), 2023, Vol.10, p.1319873-1319873
issn 2296-861X
2296-861X
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_1fbdfd23842e4deda7e8aeac7ba20389
source PubMed Central(OpenAccess)
subjects autochthonous strains
B. infantis LMG11588
Bifidobacterium-rich microbiota
infant growth
safety
title Safety, efficacy, and impact on gut microbial ecology of a Bifidobacterium longum subspecies infantis LMG11588 supplementation in healthy term infants: a randomized, double-blind, controlled trial in the Philippines
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A12%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety,%20efficacy,%20and%20impact%20on%20gut%20microbial%20ecology%20of%20a%20Bifidobacterium%20longum%20subspecies%20infantis%20LMG11588%20supplementation%20in%20healthy%20term%20infants:%20a%20randomized,%20double-blind,%20controlled%20trial%20in%20the%20Philippines&rft.jtitle=Frontiers%20in%20nutrition%20(Lausanne)&rft.au=Capeding,%20Maria%20Rosario%20Z&rft.date=2023&rft.volume=10&rft.spage=1319873&rft.epage=1319873&rft.pages=1319873-1319873&rft.issn=2296-861X&rft.eissn=2296-861X&rft_id=info:doi/10.3389/fnut.2023.1319873&rft_dat=%3Cproquest_doaj_%3E2909087621%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c362t-789fdb3e7c24dfb3558706327d895d2f56c45028370fff9094c54398668c79933%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2909087621&rft_id=info:pmid/38162520&rfr_iscdi=true